ArisGlobal, a provider of solutions to the life sciences industry, announced the agCenter? 3.1, a clinical research investigator site portal that facilitates and streamlines the communication and collaboration between sponsors and their clinical study sites.
ArisGlobal, a provider of solutions to the life sciences industry, announced the agCenter™ 3.1, a clinical research investigator site portal that facilitates and streamlines the communication and collaboration between sponsors and their clinical study sites. agCenter addresses a key challenge that sponsors face in how to best retain and recruit investigators who often experience difficulties in meeting their study obligations. The investigator portal is the newest addition to ArisGlobal’s Total Clinical™, a comprehensive platform for clinical research that includes EDC, CTMS, ePRO, medical coding, trial disclosure, supply chain management and safety reporting -- all accessed via agWorld™, a central clinical portal.
“Finding and engaging with clinical study sites is becoming increasingly challenging labor-intensive and expensive, especially with today’s complex, global trials,” commented Simon Sparkes, senior vice president and head of the Clinical and Compliance business units at ArisGlobal. “As a result, all Sponsors are looking for ways to improve site relationships while containing costs. As EDC reaches almost full adoption, Sponsors now recognize that investigator portals represent an important step forward in improving site relationships, reducing site start-up times and also reducing the high cost of site management.”
From its intuitive dashboard, agCenter offers the full range of functionality to meet the needs of both sponsors and investigators:
agCenter 3.1 will be delivered to customers as a cloud-based solution via agOnDemand™, ArisGlobal's highly proven Software-as-a-Service (SaaS) delivery platform.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.